FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a vaccine composition for inducing a protective immune response to a virus and a method of preventing a viral infection involving administering a vaccine composition, where the virus is selected from a group consisting of respiratory syncytial virus (RSV), rabies virus, Ebola virus and influenza virus. In one version of the invention, the vaccine composition contains a nanoparticle containing a core which contains a non-ionic detergent, and a viral glycoprotein associated with the nucleus, wherein the viral glycoprotein is selected from a group consisting of F-glycoprotein RSV, Ebola virus glycoprotein, rabies virus G-protein, influenza virus haemagglutinin (HA) protein, influenza virus neuraminidase (NA) protein and combinations thereof.
EFFECT: invention extends the range of agents for inducing an immune response to a virus.
23 cl, 50 dwg, 1 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGENIC POLYPEPTIDES BASED ON THE RESPIRATORY SYNCYTIAL VIRUS SEQUENCE | 2019 |
|
RU2807992C2 |
| RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
| STABILIZED F RSV PROTEINS AND THEIR USE | 2019 |
|
RU2795459C2 |
| RSV PROTEINS IN PRE-CONFLUENCE CONFORMATION AND USE THEREOF | 2014 |
|
RU2761631C2 |
| F RSV PROTEIN MUTANTS | 2016 |
|
RU2788403C2 |
| PROTEIN F RSV MUTANTS | 2016 |
|
RU2723039C2 |
| RECOMBINANT pMHC MOLECULES OF CLASS II | 2017 |
|
RU2777115C2 |
| ENGINEERED MULTI-SPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS IN THE CH2-CH3 REGION | 2018 |
|
RU2804031C2 |
| MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
| MESSENGER RNA VACCINES AGAINST WIDE RANGE OF CORONAVIRUS VARIANTS | 2022 |
|
RU2826172C2 |
